This activity is expired and is no longer available for CME credit.


Medical Retina Update: News You Can Use in Clinical Practice

Author(s)/Faculty: David M. Brown, MD, FACS; W. Lloyd Clark, MD
Release Date: 7/30/2021Expiration Date: 7/29/2022
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
The integration of anti-vascular endothelial growth factor (VEGF) injection protocols into management strategies for neovascular age-related macular degeneration (nAMD) and diabetic retinopathy (DR) has led to the enhancement of visual outcomes for these patients. Early intervention with anti-VEGF therapies in DR has demonstrated reductions in vision-threatening complications and significant slowing of disease progression. In nAMD, significant visual acuity gains observed with anti-VEGF therapy in pinnacle clinical studies have not been replicated in the real world, due to loss of patient compliance associated with treatment burden. Dosing strategies are evolving to maintain initial visual acuity gains while extending the time between dosing intervals. In the CME activity, experts in the field examine injection protocols that have demonstrated improvements in the long-term management of retinal diseases, as well as assess new evidence regarding the value of early treatment for the improvement of outcomes in patients with retinal diseases.